NEW YORK (GenomeWeb News) – Epigenomics and Wuhan Kindstar Clinical Diagnostics today announced a licensing and supply deal for the Epi proLung tissue assay for the Chinese market.
The terms of the deal call for Kindstar to commercialize Epigenomics' assay, while the Berlin-based company will manufacture and supply it. Epigenomics also will provide support "with respect to medical and regulatory considerations."
Financial and other terms of the deal were not disclosed.
"The ability to leverage the established know-how and existing and well-functioning reference laboratory infrastructure of our new partner will provide a significant advantage for Epigenomics in the market introduction and technology roll-out of Epi proLung in China," Noel Doheny, CEO of Epigenomics' US subsidiary, said in a statement. "This agreement allows for a dual commercialization effort to apply Epigenomics' patented methods and its biomarker for lung cancer diagnosis in the Chinese market."
Kindstar provides esoteric diagnostic testing to hospital and physicians in China.